

In HDV sub-genotypes 1, the high degree of genetic variability can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity

L. Piermatteo¹, G. Torre¹, L. Carioti², S. D'Anna¹, A. Magnapera¹, S. Khan², I. Etogo¹, A. Bertoli^{2,3}, P. Paba³, A. Olivero⁴, E. Teti⁵, A. Di Lorenzo⁵, V. Malagnino⁵, M. lannetta⁵, L. Baiocchi⁶, S. Francioso⁶, I. Lenci6, U. Cillo⁷, A. Vitale⁷, G. Brancaccio⁸, A. Ciancio⁴, F. Ceccherini-Silberstein², S. Grelli^{2,3}, L. Sarmati⁵, P. Lampertico¹⁰, M. Rizzetto⁴, G. P. Caviglia⁴, R. Salpini¹, V. Svicher¹

Contact information Lorenzo Piermatteo lorenzo.piermatteo@uniroma2.it

1 Department of Biology, University of Rome "Tor Vergata", Rome, Italy; 3 Unit of Virology, Tor Vergata Polyclinic Foundation, Rome, Italy; 4 Department of Medical Sciences, University of Turin, Italy; 5 Department of Systems Medicine, Infectious Disease Clinic, University of Rome "Tor Vergata", Rome, Italy; 6 Hepatology Unit, Policlinico Tor Vergata, Rome, Italy; 7 TOR VERGATA Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; 8 Department of Molecular Medicine, Infectious Diseases, University of Padova, Padua, University of Padova, University of Padova, Padua, University of Padova, Padova, Padua, University of Italy; 9 Infectious Disease Unit, University L. Vanvitelli, Naples, Italy; 10 Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;

Introduction

- Both Hepatitis Delta Antigen isoforms (HDAg) are characterized by different functional domains interspersed by inter-domains (ID):

- **RNA-Binding Domains (RBD):** Bind HDV RNA, crucial for replication.
- **Coiled-Coil Sequence (CCS):** Supports protein-protein interactions and HDAg oligomerization.
- Nuclear Localization Sequence (NLS): Directs HDAg to the nucleus for replication.
- Virus Assembly Signal (VAS): Enables genome packaging and interaction with HBV envelope proteins.

- 18 Cytotoxic T lymphocytes (CTLs) domains are present on HDAg (Kohsar et al. 2021, JHEP *Reports*) and they stimulate host CD4+ and CD8+ cells. CD8+ T cells recognize infected hepatocytes via epitopes, leading to the destruction of infected cells and limiting viral replication. In chronic Infection, persistent HDV infection results in immune escape mutations in T cell epitopes.

- HDV genome is characterized by an auto-catalytic activity thanks to a 85 bp region of RNA named ribozyme characterized by four double-stranded domains (P1, P1.1, P2, P3, and P4), three single-stranded regions (J1/2, J1.1/4, and J4/2) and 2 loop regions (L3 and L4).

So far, paucity of information is available on the extent of HDV genetic diversification in HDAg domains and Cytotoxic T lymphocytes (CTL) epitopes across the different sub-genotypes 1 and their correlation with virological and biochemical parameters.

Aim

The aim of the study is to evaluate:

- the genetic diversity of HDV within sub-genotype 1 by assessing nucleotide and amino acid conservation in key regions of HDAg and the ribozyme,
- the conservation of CTL epitopes
- The correlation of genetic variability with biochemical markers such as ALT levels.

Method

We included **103** individuals with an available serum sample, from different Italian centers (Milan, Turin, Padua and Rome).

HDV full length sequences were obtained through the following steps:



1 RNA Extraction





3 NGS Sequencing

After sequencing, the following bioinformatic steps were performed:

2 Step-PCR Amplification





- MAFFT alignment Iqtree for phylogenetic tree Maximum likelihood tree 1000 bootstraps
- Figtree for visualization

6 Phylogenetic Analysis





Results

Sub-genotypes 1 are characterized by a conspicuous degree of genetic diversification that has led to the selection of divergent genetic signatures.

Sub-genotype 1c and 1e are characterized by specific divergent mutational pathways

Mut	1c (N=49)	1e (N=46)	HDAg domain	CTL domain	P-value
I16V/T	34 (69.4)	1 (2.0)	RBD1	-	<0.001
N22S	14 (28.6)	0 (0.0)	RBD1	-	<0.001
D47E	21 (42.9)	0 (0.0)	CCS	1, 13	<0.001
R112K	22 (44.9)	0 (0.0)	ID4	8, 11, 15	<0.001
T180A	15 (30.6)	0 (0.0)	ID5	-	<0.001
A202S	19 (38.8)	2 (4.1)	VAS	7, 18	<0.001
D29E	0 (0.0)	13 (26.5)	RBD1	12	<0.001
D46E	0 (0.0)	20 (40.8)	CCS	1, 13	<0.001
K113R	0 (0.0)	13 (26.5)	ID4	11, 15	<0.001
R131K	0 (0.0)	16 (32.7)	ID4	15, 16	<0.001
M171L	1 (2.0)	11 (22.4)	ID5	5, 15	<0.001
I188V	0 (0.0)	10 (20.4)	ID5	17	<0.001

The table reports the percentage of the different mutations in the groups of individuals with HDV subgenotype 1c (green) compared to those with genotype 1e (light blue). Statistically significant differences have been calculated by Chi-squared test.

Notably, co-presence of I16V, D47E, and A202S in 1c showed significantly increased levels of ALT levels >3ULN

The graph reports the percentage of individuals vith ALT levels 3 times upper than normal limit JLN) in the groups of individuals with the Ag mutations I16V/T+D47E+A202S (light to those without this bination (orange). Statistically significant differences have been calculated by Chiauared test

- The enrichment of mutations in HDAg functional domains and CTL epitopes could hamper HDV recognition by immune response and in turn enhance the viral replication.
- The co-presence of specific mutations (I16V/T, D47E, and A202S) in HDV sub-genotype 1c are strongly associated with elevated ALT levels (>3× ULN), suggesting that these mutations may enhance viral replication and contribute to increased liver inflammation, highlighting the need for targeted therapeutic and diagnostic approaches
- Overall, the role of the high degree of genetic variability in affecting the proper HDV detection by the currently available diagnostic assays deserves further investigation.

Acknowledgements

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194735. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, Vaccines Europe, and Roboscreen. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.